Heartbeam

Heartbeam AAQS

The The AAQS of Heartbeam (BEAT) as of Oct 29, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Heartbeam has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Heartbeam in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Heartbeam AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
2.00 USD
Jan 1, 2019
2.00 USD
Jan 1, 2020
2.00 USD
Jan 1, 2021
2.00 USD
Jan 1, 2022
2.00 USD
Jan 1, 2023
2.00 USD
Jan 1, 2024
2.00 USD
Jan 1, 2025
2.00 USD
The Heartbeam AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Heartbeam Stock analysis

What does Heartbeam do? HeartBeam, Inc. generates revenue through its proprietary VECG technology platform, which includes two patented products: HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software designed for acute care settings, offering 3D comparison of baseline and symptomatic 12-lead ECG to detect heart attacks. HeartBeam AIMIGo is a credit card-sized 12-lead ECG device paired with a smartphone app and cloud-based diagnostic software for remote heart attack detection. The company targets healthcare facilities and remote monitoring segments, focusing on cardiovascular diagnostic solutions for both in-hospital and out-of-hospital settings. HeartBeam AIMI is sold to acute care providers such as hospitals and emergency departments, while HeartBeam AIMIGo serves patients and remote healthcare services seeking continuous cardiac monitoring. The firm's revenue streams derive from the commercialization of these two products, leveraging its patented VECG technology to provide higher resolution ambulatory ECG solutions. The company's focus on detecting and monitoring cardiac disease outside traditional healthcare facilities drives its product development and sales strategy. HeartBeam Inc. operates in the cardiovascular diagnostic technology sector, with its products designed to enable cardiac disease detection both inside and outside healthcare facilities. The firm's VECG platform allows for 3D vector imaging of cardiac electrical activity, enhancing diagnostic capabilities beyond standard ECG methods. Revenue is generated through the sale of software, devices, and cloud-based diagnostic systems tailored to specific healthcare environments and remote monitoring needs. Heartbeam is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Heartbeam stock

The AAQS of Heartbeam is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Heartbeam since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Heartbeam

All Key Metrics — Heartbeam